2]- Filtered low molecular Microglobulin weight protein Functional marker Decreased proximal tubular reabsorption in AKI BTP Filtered low molecular weight protein Functional marker Urinary albumin Prognostic marker of kidney disease N-acetyl-/3-(D)- Increased urinary glucosaminidase excretion in AKI Kidney injury Upregulated in AKI molecule-1 Potential marker of CKD progression Neutrophil Upregulated in AKI gelatinase Potential marker of CKD associated progression lipocalin Interleukin-18 Upregulated in AKI Liver-type fatty Increased translocation to acid binding tubular lumen in AKI protein marker of CKD progression Exogenous Inulin Inert polysachharide Gold standard for GFR measurement Iohexol Radiographic contrast agent Iothalamate
Radiographic contrast agent Radionuclide [sup.
Patient preparation and protocols for iothalamate (Conray) administration and subsequent timed blood and urine collections were as described (8).
We calibrated the CE-UV method using 3, 6, 12, 30, and 60 mg/L calibrators prepared using a 600 g/L stock solution of injectable USP grade Conray iothalamate meglumine.
Eight multiple reaction monitoring (MRM) transitions were acquired during this study, with the singly-charged precursor ion of iothalamate at the mass-to-charge ratio (m/z) of 614.
We made controls by adding Conray 60% USP to plasma and urine samples that did not contain iothalamate.
We calculated iothalamate concentration by area under the curve using 1/x weighing with respect to the internal standard and linear regression to extrapolate calibration curves with 32 Karat[TM] software (Beckman Coulter) for CE-UV and Analyst[R] software (Applied Biosystems) for LC-MS/MS.
We calculated the limit of quantification (LOQ) for iothalamate as the response resulting in a CV <20% and recovery of 80%-120% and the limit of detection (LOD) using 3 SDs from the background signal of a zero calibrator.
This overall measure of clinical performance included error components from several sources: measurement of serum creatinine, including specimen nonspecificity effects and the effects on determinants of serum creatinine other than GFR, including generation, secretion, and elimination; and from measurement of GFR as iothalamate clearance, including physiologic differences in renal function and various comorbid conditions.
Measurement of glomerular filtration rate utilizing a single subcutaneous injection of 1251-sodium iothalamate.
High-performance liquid chromatographic determination of paminohippuric acid and iothalamate in human serum and urine: comparison of two sample preparation methods.
Simultaneous determination of paminohippuric acid, acetyl-paminohippuric acid and iothalamate in human plasma and urine by high-performance liquid chromatography.
GFR determined by nonradiolableled iothalamate using capillary electrophoresis.